Showing posts with label journal of epidemiology. Show all posts
Showing posts with label journal of epidemiology. Show all posts

Wednesday, 1 March 2017

Unique Epidemiological Patterns and Origin of the Outbreak of Human Infection with H7N9 AIV in China from 2013 to 2015



An epidemic of human infection (h-H7N9 AI) with a novel Avian Influenza A (H7N9) virus (h-H7N9 AIV)broke out in China in 2013. The first case occurred in Shanghai on February 19, 2013, neighbouring provinces were involved in the next months. Until May 10, 2013, 131 confirmed cases had been reported to the World Health Organization (WHO), of which 32cases died (24.4%). 
H7N9 AIV


It was considered that the incidence and mortality were both high. Six hundred and twenty eight cases were confirmed up to April, 2015. Until June 2016, 767 cases had occurred only in the mainland with inputting cases in other regions and countries. It was suggested that the human infection with H7N9 AIV is “Natural Focus Disease” and the “Natural Focus” is in mainland China, therefore, it cannot be spread outward. “Natural Focus Disease” often is referred to as “Zoonosis” by most scholars in scientific papers.  Read more>>>>>>>>>>>>>>

Monday, 9 January 2017

Complementary and Alternative Medicine (CAM) and the Public Health



Public health is commonly defined as ‘the science and art of preventing disease, prolonging life and promoting healththrough the organised efforts of society’. It centres on promoting and protecting the health of communities, individual citizens and the wider population. 

Complementary and Alternative Medicine


Epidemiology with its focus on exploring and identifying the determinants of ill-health and why and how some stay healthy, and by extension health inequalities is a core contributory discipline generating evidence on influences, causes and potential ways to break the causal chain, thus enhancing health In a European context where a cross-country average of 3% is spent on prevention one must question why a greater proportion of healthcare expenditure is not targeted and invested ‘upstream’ with a view to addressing the root socio-economic and cultural causes of ill-health and health inequalities, thus, intervening with whom or whatever is ‘pushing them into the river’. Read more>>>>>>>>>>>>>

Thursday, 8 December 2016

Ebola Virus Disease: A Biological and Epidemiological Perspective of a Virulent Virus

Ebola disease is acute, serious and often fatal if no treatment and preventive measures are put in place. The virus is endemic in the sub-Saharan Africa where it causes major as well as minor epidemics. Mitigation strategies have not been well understood because of the easy transmission of disease among humans. There are no approved drugs for treatment while vaccines are being tested for human safety. bola genus is subdivided into five speciesi.e., Zaire, Ivory Coast, Sudan, Reston and Bundibugyo. 

Ebola Virus Disease


The risk of infection with Ebola virus is associated with three behaviours which are, close contact with an infected person in the later stages of infection; caring for a person with an Ebola infection or when preparing the deceased for a decent burial. Viral pathogenesis: Data on disease pathogenesis has been obtained from laboratory studies that employ nonhuman primates such as monkeys, baboons and other animals such as mice. Prevention and control strategies rely on employing different interventions in case management, surveillance and contact follow-up, provision of good laboratory services as well as safe burials. For the control of outbreaks, there should be community engagement and training to increase awareness on disease risk factors. Read more........................

Tuesday, 22 November 2016

Enhance the FDA's Postmarketing Drug Surveillance System of Adverse Effects through the Electronic Healthcare Data



In Drug Administration (FDA), a Federal Agency of the United States Department of Health and Human Services, before marketing (open to the public use). The FDA has a systematic premarketing risk identification and assessment system and makes decisions to approve or not approve a drug to treat a specific condition, based on a benefit-risk analysis for the intended population. Once approved,drugs move swiftly into the market place for use by prescribers and patients. 
Electronic Healthcare Data


The FDA also has a postmarketing drug surveillance and risk assessment system with intention to identify unexpected short- and long-term risks of approved drugs or products, which currently relies primarily on two methods of adverse event reporting to the FDA. One is the direct, voluntary reporting by health professionals and consumers. The other is a mandated reporting by pharmaceutical manufacturers that is mainly based on the voluntary submission of reports from medical facilities, health professionals, and consumers, so-called MedWatch program. The spontaneous case reports from health professionals like the MedWatch program are important, but may miss over 90% of all cases with rare toxic events. Read more.....................